Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Login/Register
EN FR

SAPHNELO®: 


Demonstrated Efficacy Profile1

SAPHNELO (anifrolumab for injection) is indicated in addition to standard therapy for the treatment of adult patients with active, autoantibody positive, systemic lupus erythematosus (SLE).

The first and only Type I IFN receptor antagonist indicated in active autoantibody positive SLE.1,2*

Click here for important information and a link to the Product Monograph discussing: 

  • Relevant warnings and precautions regarding use of concomitant biologic therapies; risk for the development of malignancies, or fatal respiratory infections and herpes zoster; caution in patients with a chronic infection, a history of recurrent infections, or known risk factors for infection; initiation of treatment in patients with any clinically significant active infection; Instructions on patients seeking medical advice if signs or symptoms of a clinically significant infection occur; If a patient develops an infection, or is not responding to standard therapy, instructions on how to monitor the patient closely and how to consider interrupting SAPHNELO therapy until the infection resolves; concurrent use of live or attenuated vaccines in patients treated with SAPHNELO; immunization prior to initiating therapy with SAPHNELO; fertility; pregnancy and in women of childbearing potential not using contraception; nursing women; risk to the breast-fed child; geriatrics; serious hypersensitivity reactions (including anaphylaxis) and angioedema.
  • Conditions of clinical use, adverse reactions, drug interactions and dosing/administration information.

Conditions of clinical use, adverse reactions, drug interactions and dosing/administration information.

IFN-1=interferon type I; PSP=patient support program; SLE=systemic lupus erythematosus.

*Comparative clinical significance has not been established.